| Platform | Type of candidate vaccine | Developer | Coronavirus target | Current stage of clinical evaluation/regulatory status Coronavirus candidate | Same platform for non-Coronavirus candidates |
| Inactivated | Inactivated + alum | Sinovac | SARS-CoV-2 | Phase 3 NCT04456595 Phase 1/2 NCT04383574 NCT04352608 | SARS |
| Non-Replicating Viral Vector | ChAdOx1-S | University of Oxford/AstraZeneca | SARS-CoV-2 | Phase 3 ISRCTN89951424 Phase2b/3 2020-001228-32 Phase 1/2 PACTR202006922165132 2020-001072-15 | MERS, influenza, TB, Chikungunya, Zika, MenB, plague |
| Non-Replicating Viral Vector | Adenovirus Type 5 Vector | CanSino Biological Inc./Beijing Institute of Biotechnology | SARS-CoV-2 | Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906 | Ebola |
| Protein Subunit | Adjuvanted recombinant protein (RBDDimer) | Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences | SARS-CoV-2 | Phase 2 NCT04466085 Phase 1 NCT04445194 | MERS |
| RNA | LNP encapsulated mRNA | Moderna/NIAID | SARS-CoV-2 | Phase 3 (not yet recruiting) NCT04470427 Phase 2 NCT04405076 Phase 1 NCT04283461 | multiple candidates |
| DNA | DNA plasmid vaccine with electroporation | Inovio Pharmaceuticals/ International Vaccine Institute | SARS-CoV-2 | Phase 1/2 NCT04447781 NCT04336410 | multiple candidates |
| DNA | DNA plasmid vaccine + Adjuvant | Osaka University/AnGes/ Takara Bio | SARS-CoV-2 | Phase 1/2 NCT04463472 |
|
| DNA | DNA Vaccine (GX-19) | Genexine Consortium | SARS-CoV-2 | Phase 1/2 NCT04445389 |
|
| DNA | DNA plasmid vaccine | Cadila Healthcare Limited | SARS-CoV-2 | Phase 1/2 CTRI/2020/07/026352 (not yet recruiting) |
|
| Inactivated | Inactivated | Wuhan Institute of Biological Products/Sinopharm | SARS-CoV-2 | Phase 1/2 ChiCTR2000031809 |
|
| Inactivated | Inactivated | Beijing Institute of Biological Products/Sinopharm | SARS-CoV-2 | Phase 1/2 ChiCTR2000032459 |
|
| Inactivated | Whole-Virion Inactivated | Bharat Biotech | SARS-CoV-2 | Phase 1/2 CTRI/2020/07/026300 |
|
| Protein Subunit | Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M | Novavax | SARS-CoV2 | Phase 1/2 NCT04368988 | RSV; CCHF, HPV, VZV, EBOV |
| Protein Subunit | RBD-based | Kentucky Bioprocessing, Inc | SARS-CoV2 | Phase 1/2 NCT04473690 |
|
| RNA | 3 LNP-mRNAs | BioNTech/Fosun Pharma/Pfizer | SARS-CoV2 | Phase 1/2 2020-001038-36 NCT04368728 |
|
| Inactivated | Inactivated | Institute of Medical Biology, Chinese Academy of Medical Sciences | SARS-CoV2 | Phase 1 NCT04412538 |
|